---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-23-000081"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T01:09:50.462733+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mineralys presents post-hoc analysis linking BMI to enhanced BP reduction with lorundrostat

## Summary
- Post-hoc analysis from Target-HTN Phase 2 trial: median systolic BP reduction of 32 mmHg in responder population.
- Enhanced response proportional to BMI; modeled reduction ~12 mmHg at BMI 30 and ~19 mmHg at BMI 40 kg/m².
- Statistically significant linear regression association between BMI and systolic BP reduction (BMI 22.5-40 kg/m²).
- Advance-HTN pivotal trial enrolling; Phase 3 Launch-HTN trial expected to start before end of 2023.
- Data supports obesity-associated aldosterone-dependent hypertensive endotype as predictor of response.

## SEC filing metadata
- accession: 0001933414-23-000081
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000081/0001933414-23-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341423000081/mlys-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-23-000081
- JSON: https://secwatch.observer/filing/0001933414-23-000081.json
- Plain text: https://secwatch.observer/filing/0001933414-23-000081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.